BRPI0410632A - piridopirazinas e uso das mesmas como inibidores de cinase - Google Patents

piridopirazinas e uso das mesmas como inibidores de cinase

Info

Publication number
BRPI0410632A
BRPI0410632A BRPI0410632-6A BRPI0410632A BRPI0410632A BR PI0410632 A BRPI0410632 A BR PI0410632A BR PI0410632 A BRPI0410632 A BR PI0410632A BR PI0410632 A BRPI0410632 A BR PI0410632A
Authority
BR
Brazil
Prior art keywords
pyridopyrazines
kinase inhibitors
medicaments
malignant
preparation
Prior art date
Application number
BRPI0410632-6A
Other languages
English (en)
Inventor
Eckhard Guenther
Eckhard Claus
Irene Seipelt
Ulf-R Rapp
Ludmilla Wixler
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BRPI0410632A publication Critical patent/BRPI0410632A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"PIRIDOPIRAZINAS E USO DAS MESMAS COMO INIBIDORES DE CINASE". A invenção refere-se a novos derivados de pirido¢2,3-b!pirazina da Fórmula geral (I), à preparação e uso dos mesmos como medicamentos, especialmente para o tratamento de distúrbios malignos e outros com base em proliferações celulares patológicas.
BRPI0410632-6A 2003-05-23 2004-05-19 piridopirazinas e uso das mesmas como inibidores de cinase BRPI0410632A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10323345A DE10323345A1 (de) 2003-05-23 2003-05-23 Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
PCT/EP2004/005379 WO2004104002A1 (de) 2003-05-23 2004-05-19 Neue pyridopyrazine und deren verwendung als kinase-inhibitoren

Publications (1)

Publication Number Publication Date
BRPI0410632A true BRPI0410632A (pt) 2006-06-13

Family

ID=33441206

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410632-6A BRPI0410632A (pt) 2003-05-23 2004-05-19 piridopirazinas e uso das mesmas como inibidores de cinase

Country Status (17)

Country Link
US (3) US7323468B2 (pt)
EP (1) EP1628976A1 (pt)
JP (1) JP2007500195A (pt)
KR (1) KR20060015283A (pt)
CN (2) CN1795195B (pt)
AR (1) AR045685A1 (pt)
AU (1) AU2004240746B2 (pt)
BR (1) BRPI0410632A (pt)
CA (1) CA2524948A1 (pt)
DE (1) DE10323345A1 (pt)
MX (1) MXPA05012592A (pt)
NO (1) NO20056030L (pt)
RS (2) RS51906B (pt)
RU (1) RU2005140378A (pt)
TW (1) TW200504062A (pt)
WO (1) WO2004104002A1 (pt)
ZA (2) ZA200508872B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
ES2316985T3 (es) * 2003-05-23 2009-04-16 Aterna Zentaris Gmbh Nuevas piridopirazidinas y su uso como moduladores de quinasas.
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
US20100132790A1 (en) * 2005-05-09 2010-06-03 Solaris Nanosciences, Inc. Rechargeable Dye Sensitized Solar Cell
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
EP1785423A1 (de) * 2005-11-11 2007-05-16 Zentaris GmbH Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
CA2628039A1 (en) 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5053394A (pt) 1973-09-20 1975-05-12
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
TW274550B (pt) * 1992-09-26 1996-04-21 Hoechst Ag
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP3795044B2 (ja) * 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc HEMMER OF ACT ACTIVITY
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
WO2004005472A2 (en) 2002-07-02 2004-01-15 Southern Research Institute Inhibitors of ftsz and uses thereof
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
JP2006512313A (ja) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
AU2004259269A1 (en) 2003-07-18 2005-02-03 Basf Aktiengesellschaft Aryl-condensed 3-arylpyridine compounds and use thereof for controlling pathogenic fungi
WO2005056825A1 (en) 2003-12-05 2005-06-23 Board Of Regents, The University Of Texas System Screening for modulators of mekk2 and mekk3
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
AU2005325267B2 (en) 2004-04-30 2010-11-04 Curis Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
GB0413955D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
GB0413953D0 (en) 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
JP2006137723A (ja) 2004-11-15 2006-06-01 Kyowa Hakko Kogyo Co Ltd スルホンアミド誘導体
US20090137558A1 (en) 2004-12-03 2009-05-28 Peakdale Molecular Limited Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products
US20070293456A9 (en) 2004-12-30 2007-12-20 Anthony Hayford Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
CN101103028A (zh) 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
CA2594998A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders

Also Published As

Publication number Publication date
AU2004240746B2 (en) 2007-05-31
NO20056030L (no) 2006-02-15
CN1795194A (zh) 2006-06-28
RS20050876A (sr) 2008-04-04
US8193186B2 (en) 2012-06-05
US20070275972A1 (en) 2007-11-29
ZA200508633B (en) 2006-07-26
RU2005140378A (ru) 2007-06-27
JP2007500195A (ja) 2007-01-11
KR20060015283A (ko) 2006-02-16
EP1628976A1 (de) 2006-03-01
CN1795195B (zh) 2010-04-21
RS51906B (sr) 2012-02-29
AR045685A1 (es) 2005-11-09
MXPA05012592A (es) 2006-02-08
AU2004240746A1 (en) 2004-12-02
US20080113991A1 (en) 2008-05-15
US7323468B2 (en) 2008-01-29
RS20050864A (sr) 2008-04-04
DE10323345A1 (de) 2004-12-16
CA2524948A1 (en) 2004-12-02
ZA200508872B (en) 2006-07-26
CN1795195A (zh) 2006-06-28
WO2004104002A1 (de) 2004-12-02
TW200504062A (en) 2005-02-01
US20050032803A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
BRPI0410632A (pt) piridopirazinas e uso das mesmas como inibidores de cinase
BRPI0410633A (pt) piridopirazinas e uso das mesmas como moduladores de cinase
NO20082511L (no) Nye pyridopyraziner og deres anvendelse som kinasemodulatorer
BRPI0514537A (pt) compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
UY27807A1 (es) Nuevos derivados de piridazin-3(2h)-ona
BRPI0513915A (pt) compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
BRPI0413695A (pt) derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
UY27604A1 (es) Compuestos químicos.
BRPI0517921A (pt) métodos para preparar compostos de indazol
PT1506185E (pt) Compostos novos e sua utilizacao
BR0316296A (pt) Compostos lapacone e seus métodos de uso
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
NO20050428L (no) Arylkarbonylpiperaziner og heteroarylkarbonylpiperaziner og anvendelse derav for behandling av godartede og ondartede tumorsykdommer
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
TW200504076A (en) 7-imino derivatives camptothecin having antitumor activity
DE60009032D1 (de) Benzolsulfonamid-derivate und ihre verwendung
BRPI0618452A2 (pt) piridopirazinas e seu uso como moduladores de cinases

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ZENTARIS GMBH (DE)

Free format text: SEDE ALTERADA CONFORME PETICAO NO 020060058923-RJ DE 27.04.2006.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.